Pharmacognosy intro
Cymbopogon citratus (DC.) Stapf, Poaceae. Leaves and stalks. Common names include lemongrass and West Indian lemongrass. One of the few grasses with significant pharmacological documentation. The essential oil is dominated by citral (70-85%), which is a mixture of two geometric isomers: geranial (alpha-citral, ~45%) and neral (beta-citral, ~35%). Secondary compounds include beta-myrcene (~10-15%), geraniol, citronellol, limonene, and trace 1,8-cineole. The anxiolytic mechanism has been directly confirmed through GABA-A receptor-benzodiazepine complex interaction. Lemongrass essential oil's anxiolytic activity was reversed by flumazenil (a competitive benzodiazepine antagonist), demonstrating that lemongrass works through the same receptor system as diazepam and alprazolam, but as a gentle modulator rather than a full agonist. At 1.0 g/kg oral dose, it significantly increased pentobarbital sleeping time, confirming sedative activity. Citral disrupts bacterial cell membrane integrity providing broad-spectrum antimicrobial coverage against bacteria, yeasts, and fungi. The essential oil also showed DNA protective action against N-methyl-N-nitrosurea-induced leukocyte damage. A human trial with 40 men (18-30 years) subjected to the Stroop Color Word Test to induce anxiety found that lemongrass essential oil aroma (3 and 6 drops) produced significant reduction in anxiety and subjective tension assessed by STAI and Social Phobia Inventory questionnaires versus control (Goes et al., 2015). This is the most direct human evidence for the anxiolytic effect. Preclinical anticancer findings are notable. Essential oils from C. citratus induced apoptosis and cell cycle arrest in A549 lung cancer cells with IC50 values of 1.73 ug/mL (A549) and 2.45 ug/mL (H1299), operating through caspase-3 activation and Bax/Bcl-2 ratio alteration via the intrinsic apoptotic pathway (Trang et al., 2020). Lemongrass essential oil also provided protective action against MNU-induced DNA damage in female mice, suggesting potential anticarcinogenic activity against mammary carcinogenesis (Bidinotto et al., 2010). Additional preclinical activity includes anticonvulsant, antipyretic, and analgesic effects, with beta-myrcene contributing independent sedative and analgesic properties.